February 13, 2020 / 9:53 PM / 12 days ago

BRIEF-Ultragenyx Reports Fourth Quarter And Full Year 2019 Financial Results

Feb 13 (Reuters) - Ultragenyx Pharmaceutical Inc:

* ULTRAGENYX REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND CORPORATE UPDATE

* Q4 LOSS PER SHARE $1.62

* Q4 EARNINGS PER SHARE ESTIMATE $-1.65 — REFINITIV IBES DATA

* REAFFIRMED ITS FINANCIAL GUIDANCE FOR 2020

* ULTRAGENYX PHARMACEUTICAL - 2020 CRYSVITA REVENUE IN ULTRAGENYX TERRITORIES GUIDANCE OF $125 MILLION TO $140 MILLION REAFFIRMED

* FOR Q4 OF 2019, ULTRAGENYX REPORTED $35.6 MILLION IN TOTAL REVENUE

* WILL NO LONGER RECEIVE CASH PAYMENTS FROM EU TERRITORY ROYALTY REVENUE RIGHTS BEGINNING JANUARY 1, 2020

* Q4 REVENUE VIEW $32.2 MILLION — REFINITIV IBES DATA

* EXPECTS A MORE THAN 20 PERCENT REDUCTION IN NET CASH BURN IN 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below